625,000 Shares in Aquestive Therapeutics, Inc. $AQST Acquired by Aberdeen Group plc

Aberdeen Group plc acquired a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 625,000 shares of the company’s stock, valued at approximately $3,494,000. Aberdeen Group plc owned approximately 0.63% of Aquestive Therapeutics at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of AQST. Commonwealth Equity Services LLC purchased a new position in shares of Aquestive Therapeutics in the third quarter valued at $5,918,000. Federated Hermes Inc. acquired a new stake in Aquestive Therapeutics in the 3rd quarter valued at about $4,381,000. Sio Capital Management LLC increased its holdings in Aquestive Therapeutics by 141.9% during the 2nd quarter. Sio Capital Management LLC now owns 947,489 shares of the company’s stock valued at $3,136,000 after acquiring an additional 555,860 shares in the last quarter. Everstar Asset Management LLC raised its position in Aquestive Therapeutics by 119.5% during the second quarter. Everstar Asset Management LLC now owns 658,607 shares of the company’s stock worth $2,180,000 after acquiring an additional 358,607 shares during the last quarter. Finally, Pale Fire Capital SE lifted its holdings in shares of Aquestive Therapeutics by 25.5% in the second quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock valued at $5,549,000 after purchasing an additional 340,767 shares in the last quarter. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

Aquestive Therapeutics Trading Down 0.3%

Aquestive Therapeutics stock opened at $3.95 on Friday. The stock has a fifty day moving average price of $4.56 and a 200 day moving average price of $5.18. Aquestive Therapeutics, Inc. has a 52 week low of $2.12 and a 52 week high of $7.55. The firm has a market capitalization of $481.90 million, a P/E ratio of -5.56 and a beta of 1.65.

Analyst Ratings Changes

AQST has been the subject of several research reports. Wall Street Zen downgraded Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Piper Sandler raised their price target on Aquestive Therapeutics from $5.00 to $8.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st. Finally, Lake Street Capital set a $6.00 price objective on Aquestive Therapeutics in a research note on Tuesday, February 3rd. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $8.50.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.